Genitourinary Cancers

Adam E. Singer, MD, PhD, details how he selects between the available TKI/IO combinations and the only dual immunotherapy regimen for patients with RCC.

David A. Braun, MD, PhD, discusses the role of biomarkers in guiding adjuvant treatment strategies for renal cell carcinoma.

Alexandra Drakaki, MD, PhD, discusses the potential role of zanzalintinib in advanced non–clear cell renal cell carcinoma.

John K. Lee, MD, PhD, discusses treatment considerations for the use of enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer.

Emre Yekedüz, MD, discusses a case study shared via social media that evaluated treatment options for a patient with clear cell renal cell carcinoma.

Rashad Nawfal, MD, discusses the association between radiologic tumor burden and OS in patients with metastatic ccRCC who had received frontline IO.

Bradley McGregor, MD, discusses how abemaciclib monotherapy did not elicit clinically meaningful activity in heavily pretreated metastatic clear cell RCC.

Nazli Dizman, MD, discusses next steps planned for research with CBM588 in patients with renal cell carcinoma in the first line.

Viktor Grünwald, MD, PhD, discusses differences in tumor burden between patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab vs sunitinib.

Bradley McGregor, MD, discusses the rationale for investigating abemaciclib monotherapy in patients with clear cell renal cell carcinoma.

Antonio Cigliola, MD, discusses potential clinical implications of data from the phase 2 SURE-01 and SURE-02 trials in MIBC.

OMX-0407 was safe and displayed activity in advanced solid tumors; dose-expansion cohorts will evaluate the agent in RCC and angiosarcoma.

Emre Yekedüz, MD, discusses a case study on a patient with clear cell renal cell carcinoma, highlighting adjuvant treatment options for this individual.

Emre Yekedüz, MD, discusses the exploration of biomarker-driven therapeutic approaches in renal cell carcinoma.

Eddy Saad, MD, MSc, the potential predictive value of IL-7 SNPs to inform treatment decisions for select patients with renal cell carcinoma.

Emre Yekedüz, MD, discusses key takeaways from IMmotion010, highlighting the importance of biomarker-driven treatment in patients with kidney cancer.

Karl Semaan, MD, MSc, discusses the clinical advantages of liquid biopsy over tissue biopsies in detecting sarcomatoid renal cell carcinoma.

Bradley McGregor, MD, discusses ongoing treatment challenges and future research directions in clear cell renal cell carcinoma.

In 2024, kidney cancer is projected to be one of the top 10 cancers in terms of incidence rate in the United States, with an estimated 81,610 new diagnoses.

Emre Yekedüz, MD, discusses a case study shared via an OncLive X poll on the adjuvant treatment of clear cell renal cell carcinoma.

Bradley McGregor, MD, discusses the future implications of evolutions in the renal cell carcinoma treatment paradigm.

Neil J. Shah, MBBS, discusses real-world outcomes of patients with metastatic RCC receiving treatment in the post-IO/TKI setting following progression.

Renee Saliby, MD, MSc, discusses the investigation of the correlation between intermediate end points and OS in metastatic renal cell carcinoma.

Renee Maria Saliby, MD, MS, discusses potential intermediate end points for overall survival in previously treated metastatic renal cell carcinoma.

David A. Braun, MD, PhD, discusses the variety of therapies available for the treatment of patients with kidney cancer.